RayzeBio Delisted
RayzeBio is a pharmaceuticals company that focuses on developing targeted radiopharmaceutical drugs for cancer. Their main goal is to improve outcomes for cancer patients by harnessing the power of targeted radioisotopes. They have a diverse portfolio of radiopharmaceutical drug candidates, ranging from discovery to late-stage clinical programs. RayzeBio aims to deliver radioisotopes that emit alpha particles, such as Actinium-225, directly to solid tumors, including metastatic ones. They are considered the emerging leader in radiopharmaceuticals and are dedicated to advancing their pipeline programs to bring innovative treatments to cancer patients.
Founded Date:
2018
Last Funding Date:
2021
Industry:
PharmTech
Last Funding Type:
Series C
Total Funding:
258000000
Headquarters:
San Diego, California, United States
Technology:
Biologics
Investor Type:
Late Stage Venture
Investors Number:
16
Employee Number:
11-50
Funding Status:
Early Stage Venture